Novel insulin derivatives, their preparation and use, and a pharmaceutical composition thereof

摘要

Insulin derivatives of the formula III …… in which … …  a) R<30> + R<31> together = OH or …  b) R<30> = residue of a neutral, genetically encodable L-amino acid and R<31> = OH or… a physiologically acceptable organic group which is basic in nature and has up to 50 C atoms, in whose structure 0 to 3 alpha -amino acids are involved and whose optionally present terminal carboxyl group can be free, in the form of an ester, of an amide or of a lactone, or reduced to CH2OH, and …  c) R = residue of a genetically encodable L-amino acid or a physiologically acceptable organic group with up to 50 C atoms, with the exception of the cases in which simultaneously R<30> = Ala, R<31> = OH, R = Lys or Arg, and the A chain and B chain are the sequences of bovine insulin, … and the physiologically tolerated salts thereof. …The compounds are suitable for the treatment of diabetes mellitus, have a delayed action profile and are very well tolerated.